U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07017699) titled 'A Study to Assess Deucravacitinib Safety in Pregnancy' on June 04.
Brief Summary: The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were exposed to deucravacitinib.
Study Start Date: March 21
Study Type: OBSERVATIONAL
Condition:
Psoriasis (PsO)
Intervention:
DRUG: Deucravacitinib
According to product label
DRUG: Other systemic treatments for PsO
According to product label
Recruitment Status: RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digi...